

RECEIVED #61645

MAR 2 2 2002

TECH CENTER 1600/2900

PATENT APPLICATION

ATTORNEY DOCKET NO.: 28384/38187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Eva-Maria Mandelkow et al.

Serial No: 10/066,810

Filed: February 4, 2002

For: Novels Tools for the Diagnosis and
Treatment of Alzheimer's Disease

Art Unit: 1645

Examiner: P. Duffy

CERTIFICATE OF MAILING
(37 C.F.R. § 1.8)

I hereby certify that this paper is
being deposited as First Class Mail on
March 8, 2002 in an envelope addressed
to the Commissioner for Patents,
Washington, D.C. 20231.

Thomas J. Wrona, Ph.D.

PRELIMINARY AMENDMENT


Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits of the above-identified application, please
cancel claims 1-32 and replace with new claims 33-66.

33. (New) An antibody that binds phosphorylated tau, wherein the antibody binds
a tau epitope comprising a serine or threonine residue only when the serine or
threonine residue is phosphorylated, said serine or threonine residue selected from the
group consisting of

-
- (a) residue 46 in SEQ ID NO:1;
 - (b) residue 50 in SEQ ID NO:1;
 - (c) residue 52 in SEQ ID NO:1;
 - (d) residue 68 in SEQ ID NO:1;
 - (e) residue 69 in SEQ ID NO:1;
 - (f) residue 71 in SEQ ID NO:1;

- 
- (g) residue 111 in SEQ ID NO:1;
 - (h) residue 113 in SEQ ID NO:1;
 - (i) residue 153 in SEQ ID NO:1;
 - (j) residue 175 in SEQ ID NO:1;
 - (k) residue 182 in SEQ ID NO:1;
 - (l) residue 184 in SEQ ID NO:1;
 - (m) residue 198 in SEQ ID NO:1;
 - (n) residue 199 in SEQ ID NO:1;
 - (o) residue 202 in SEQ ID NO:1;
 - (p) residue 205 in SEQ ID NO:1;
 - (q) residue 208 in SEQ ID NO:1;
 - (r) residue 210 in SEQ ID NO:1;
 - (s) residue 212 in SEQ ID NO:1;
 - (t) residue 214 in SEQ ID NO:1;
 - (u) residue 217 in SEQ ID NO:1;
 - (v) residue 220 in SEQ ID NO:1;
 - (w) residue 231 in SEQ ID NO:1;
 - (x) residue 235 in SEQ ID NO:1;
 - (y) residue 237 in SEQ ID NO:1;
 - (z) residue 238 in SEQ ID NO:1;
 - (aa) residue 262 in SEQ ID NO:1;
 - (bb) residue 263 in SEQ ID NO:1;
 - (cc) residue 293 in SEQ ID NO:1;
 - (dd) residue 324 in SEQ ID NO:1;
 - (ee) residue 356 in SEQ ID NO:1;
 - (ff) residue 361 in SEQ ID NO:1;
 - (gg) residue 400 in SEQ ID NO:1;
 - (hh) residue 403 in SEQ ID NO:1;
 - (ii) residue 404 in SEQ ID NO:1; and
 - (jj) residue 422 in SEQ ID NO:1.